Early surgery or close monitoring for an enlarged ascending aorta
Compares early aorta replacement surgery with regular monitoring in adults with ascending aortic aneurysm.
Key facts
- Who runs it
- Ottawa Heart Institute Research Corporation
- Where
- Ann Arbor, Boston, Charleston, Cleveland, Columbus, Durham, Houston, Iowa City, New York, Philadelphia, Plano, Ridgewood, Rochester, San Francisco, and St Louis, United StatesSee the 16 sitesAlso in 2 other countries, 15 sites
- Trial code
- Registry title
- Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
- Status
- Recruiting
- People taking part
- 610 people, planned
- Started
- 1 Sept 2018
- Expected to end
- 31 May 2035
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Thoracic Aortic Surgery
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a widened ascending aorta (aneurysm) of 5.0cm (2 in) to 5.4cm (2.1 in). People are randomly put into early surgery or close monitoring.
- Age
- 18 to 79 years
- Sex
- All sexes
- Disease stage
- Ascending aortic aneurysm between 5.0cm (2 in) and 5.4cm (2.1 in) at its widest, measured by CT with contrast. It must cause no symptoms. People with 4.5 cm (1.8 in) - 4.9 cm (1.9 in) are watched with CT scans and can join once it reaches 5.0 cm (2 in).
- Earlier treatment
- People who had heart surgery before cannot join.
Main reasons for not taking part
- Known connective tissue disease (such as Marfan, Loey-Dietz or Turner syndrome) or possible inherited aorta disease
- Aneurysm growing faster than 0.5 cm/year during the past 5 years, or involving the descending aorta
- Inflammation of the arteries (such as Takayasu's or syphilitic arteritis)
- Pregnant or planning to become pregnant
- Not fit enough for surgery, for example severe lung disease, NYHA III or IV heart failure, heart attack within 6 months, or expected survival under 5 years
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patients between the age of 18 and 79 inclusive
- Ascending aortic aneurysm between 5.0cm and 5.4cm in maximal diameter as measured by CT with contrast
- Patients with ascending aortic aneurysm with a diameter of 4.5 cm - 4.9 cm will be observed with serial CT, and will be considered for enrollment into the trial once the aneurysm reaches 5.0 cm
Who cannot take part
- Previous cardiac surgery
- Patients whose primary indication for cardiac surgery is non-AsAA related
- Patients with known connective tissue disease (E.g. Marfan syndrome, Loey-Dietz syndrome, Turner syndrome etc) syndrome, etc.)
- Patients with possible genetic aortopathies (eg known family history of aortic aneurysms/premature aortic dissections/ruptures)
- Patients who have a history or presence of a medical condition or disease or psychiatric condition that in the investigator's assessment would render the subject ineligible for study participation
- Patients who, in the opinion of the investigator, are deemed unfit for surgery for reasons that may include:; Severe pulmonary disease; Cr = 250umol/L; Child Pugh Class B or C; NYHA III or IV; MI within the last 6 months; Major surgical procedure or angioplasty within 3 months; Expected survival less than 5 years because of other disease (e.g. invasive cancer)
- Patients who refused to be randomized
- Patients with symptomatic attributable to ascending aortic aneurysms
- Patients who are unable to provide informed consents
- Patients who are unable to attend for regular follow-up/ remain compliant with protocol
- Known AsAA expansion rate exceeding 0.5 cm/year during the past 5 years
- Arch aneurysms with no ascending aorta involvement (no aneurysmal segments before the innominate artery)
- Ascending aortic and arch aneurysm with descending thoracic aorta involvement
- Patients with inflammatory arteritis (e.g. takayasu's arteritis, syphilitic arteritis, etc.)
- Female patients who are pregnant or planning to become pregnant
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Where in United States
Also in 2 other countries, 15 sites
- University of MichiganAnn Arbor, United StatesContact: Himanshu Patel, MD (principal investigator)Taking people
- Beth Israel Deaconess Medical CenterBoston, United StatesContact: Jenifer KaufmanTaking people
- Massachusetts General HospitalBoston, United StatesContact: Arminder Jassar, MD (principal investigator)Taking people
- MUSC Health University Medical CenterCharleston, United StatesContact: Hannah CulpepperTaking people
- University Hospitals ClevelandCleveland, United StatesContact: Nisreen ZueiterTaking people
- Ohio State University Medical CenterColumbus, United StatesContact: Jovan Bovinovski, MD (principal investigator)Taking people
- Duke UniversityDurham, United StatesContact: G. Chad Hughes, MD (principal investigator)Taking people
- University of Texas Health Science CentreHouston, United StatesContact: Anthony Estrera, MD (principal investigator)Taking people
- University of IowaIowa City, United StatesContact: Gawain J WilliamsTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Ismail El-Hamamsy, MD (principal investigator)Taking people
- The Trustees of the University of PennsylvaniaPhiladelphia, United StatesContact: Nimesh Desai, MDTaking people
- Baylor Scott & White Research InstitutePlano, United StatesContact: William Brinkman, MD (principal investigator)Taking people
- The Valley Hospital Inc.Ridgewood, United StatesContact: Juan Grau, MD (principal investigator)Taking people
- Mayo ClinicRochester, United StatesContact: Disrud LeviTaking people
- University of California at San Francisco Medical CenterSan Francisco, United StatesContact: Elaine Tseng, MD (principal investigator)Taking people
- Washington University School of MedicineSt Louis, United StatesContact: Allison SchuckTaking people
About the trial
What the trial wants to find out
The ascending aorta conducts blood from the heart to the rest of the body. The ascending aorta can become enlarged, and the risk of tearing and rupturing becomes higher with larger aorta. When the ascending aorta tears or ruptures, the risk dying is high even if surgery is done as soon as possible. Traditionally, when the ascending aorta gets above 5.5 cm, surgery is recommended to replace the aorta. However, this threshold is based relatively weak evidence, and sometimes patients with smaller aorta can tear or rupture. On the other hand, surgery carries its own risk as well. Since there are risk of waiting or doing surgery, there is currently no great support for either approach for patients with a smaller aorta. In the TITAN SvS trial, patients with an ascending aorta between 5.0 to 5.5 cm is assigned by chance to the early surgery group, in which they will undergo replacement of aorta, or the surveillance group, in which they will be closely monitored. The chance of dying or suffer tearing or rupture of aorta between the two groups will be compared. The result of the trial will guide future practice for patients with enlarged ascending aorta.
Read full original descriptionShow less
This is a prospective, multi-centre randomized control trial that compares the all-cause mortality, aneurysm-related aortic events, rate of stroke, and quality of life for those patients undergoing early elective ascending aortic surgery to those patients undergoing surveillance. Patients referred for an ascending aortic aneurysm that meets the inclusion criteria will be randomized to the early elective surgery group or the surveillance group. Recruitment will end when the desired sample size is reached, and the patients will be followed for a minimum 2-year period. The primary objective of the trial is to compare the composite outcome of the all-cause mortality and incidence of acute aortic events between surveillance and elective ascending aortic surgery for patients with degenerative or bicuspid valve-related ascending aortic aneurysm after 2 years of follow up. The hypothesis is that the early surgery group will have a significantly lower all-cause mortality and incidence of acute aortic events at 2 years of follow up compare to the surveillance group. The result of this trial will provide evidence based guidance in the appropriate management of ascending aortic aneurysm based on the size criteria, and establish a large database for future investigations.
The 2 groups in the trial
- Surveillance ArmNo study treatment, for comparison
Patients in the Non-Operative Registry will be followed in clinic annually with a CT scan to monitor the status of their ascending aortic aneurysm, until the end of the study, the occurrence of an aortic event, or death.
- Surgery/Treatment ArmOther group
Patients in the Operative Registry will have thoracic aortic surgery
Treatment: Thoracic Aortic Surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance (TITAN:SvS)
- Plain-language title
- Early surgery or close monitoring for an enlarged ascending aortaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT03536312, who can take part
- Publications
- Impact of nondiameter aortic indices on surgical eligibility: Results from the Treatment in Thoracic Aortic Aneurysm: Surgery Versus Surveillance (TITAN: SvS) randomized controlled trial.The Journal of thoracic and cardiovascular surgery, 2025
- Protocol for a randomised controlled trial for Treatment in Thoracic Aortic Aneurysm: Surgery versus Surveillance (TITAN: SvS).BMJ open, 2021
- Record updated
- 2 November 2026